



**U.S. FOOD & DRUG
ADMINISTRATION**

FDA CDER NextGen Portal

Regulatory Education for Industry (REdI) Annual Conference – 2023

Seyoum Senay

Supervisory Operations Research
Office of Business Informatics (OBI)
Center for Drug Evaluation and Research (CDER)
US FDA



FDA Disclaimer

The views and opinions presented here represent those of the speaker and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.

Agenda

What is CDER NextGen Portal?


Before and After NextGen Portal

What is New ?

User's Adoption



What is CDER NextGen Portal?




CDER NextGen Portal:




One stop shop for the purpose of non-eCTD Submission, Collaboration and Reporting. The portal enables sponsors to submit Drug Shortages Notifications and exempted human drug applications. This collaboration capability continues to reduce regulatory overhead for sponsors, academia, research institutes, and small businesses.

The FDA Digital Transformation


in action to promote safe and effective human drug review and approval




Before NextGen Portal






-  Inefficient paper and Media processing
-  Manually intensive
-  Time and resource consuming

After NextGen Portal



-  Streamlined submissions with clean, complete, and validated data
-  Maximized API led technology to improve efficiency
-  Improved collaboration between the FDA and Stakeholders

FDA CDER NextGen Portal Products for non eCTD Submission, Collaboration and Reporting

	 Regulatory Submissions	 Collaboration	 Reporting
Drug Shortages Notifications			✓
Research IND Application Builder	✓	✓	
CARES Volume Act Reporting	✓		✓
Alternate Submissions (Non eCTD Type III DMFs, EUA and others)	✓		
Orphan Drug	✓	✓	
Drug Development Tools		✓	
Controlled Correspondence	✓	✓	
Pre-ANDA & CPAM Meeting Request	✓	✓	
Pre-Assignment Number	✓	✓	
Waiver Exemption Exceptions Request	✓	✓	
Program Fee	✓		✓
Standards Recognition		✓	✓
Extensions Requests			✓
Manufacturing Capacity			✓
Critical Care Drug Monitoring Portal			✓
Radioactive Drug Research Committee			
Potential Drug Shortage		✓	
Emergency Use Potential Drug Shortage	✓	✓	
Pre-Launch Activities Importation Requests		✓	
OMUFA	✓	✓	

What's New? CDER NextGen Portal **Products**



CARES Volume Act

As part of the Coronavirus Aid, Relief, and Economic Security Act, 2020 Enacted H.R. 748, 116 Enacted H.R. 748. Registrants/Establishments with business operations, who have registered and/or listed products with the FDA CDER using SPL should be able to provide volume information.



Controlled Correspondences

Through the CDER NextGen Portal, stakeholders enabled to submit their correspondence for streamlined communication with the FDA CDER



Pre-ANDA Meeting Request (CPAM)

Stakeholders enabled to submit product development, pre-submission, and combination product meeting requests for complex generic drug products by uploading meeting requests and meeting packages for more efficient processing.



Pre-Launch Activities Importation Requests (PLAIR)

Section 505(A) of the FD&C Act prohibits the introduction of any new drug into interstate commerce unless there is an approved application filed for that drug; however, Industry can submit a pre-launch activities importation request (PLAIR) in preparation for market launch within 60 days of the anticipated decision date for a pending initial original marketing application.

What's New? CDER NextGen Portal – CARES Volume Act



CARES Volume Act

As part of the Coronavirus Aid, Relief, and Economic Security Act, 2020 Enacted H.R. 748, 116 Enacted H.R. 748. Registrants/Establishments with business operations, who have registered and/or listed products with the FDA CDER using SPL should be able to provide volume information.

A new process to replace existing submissions

CARES Act Amount Information Reporting

APPLICATION BUILDER:

☐ Submitter Information

☒ Submission

[Need Help?](#)

Submission

Submission Information

*What year are you submitting for?

2022

Are you submitting a replacement report for a previous submission?

☐ Yes

*Would you like to submit product data manually or by uploading data from a CSV file?

☐ Manually

☒ CSV File

For Uploading Data Using the CSV Template

Please download and fill out the following template. Once complete, save as a .csv extension type file and return back to the portal to upload data from csv file.

[CARES Template for CSV Data Upload.xlsx](#)

Instructions for Using the CSV Template

[CARES CSV Template Instructions.pdf](#)

For Uploading Data Using a Custom CSV File

Instructions for Using a Custom CSV File

[CARES CSV Custom File Instructions.pdf](#)

Enhanced functionality to view previously submitted reports from the landing page

A new process to submit a CSV file

What's New? CDER NextGen Portal – GDUFA III



Controlled Correspondences

Through the CDER NextGen Portal, stakeholders enabled to submit their correspondence for streamlined communication

The screenshot shows the 'Controlled Correspondence' form. On the left is an 'APPLICATION BUILDER' sidebar with tabs for 'Contact Details', 'Correspondence Info', 'Product Details' (selected), 'Upload Documents', and 'Review & Submit'. Below this is a 'Need Help?' section. The main area is titled 'Product Details' and contains 'Product Information' fields. These include two screening questions: 'Is this request related to post-approval submission requirements that are not specific to an ANDA?' and 'Is this request related to your previously submitted ANDA or pre-assigned ANDA?'. Below these is a text field for 'ANDA Number(s)' with the value '123111'. A dropdown menu for 'What is the status of the ANDA?' is highlighted with a blue box and shows 'Pending'. Below this is another screening question: 'Have you had a Product Specific Guidance (PSG) teleconference with the FDA?'. At the bottom, there is a question: 'Is this request related to inactive high priority drugs?'.

1. Additional status type of Pending for ANDAs
2. Added screening questions



Pre-ANDA Meeting Request (CPAM)

Stakeholders enabled to submit product development, pre-submission, and combination product meeting requests for efficient processing.

1. Addition of meeting types
2. Additional questionnaires to streamline communication

The screenshot shows the 'Pre-ANDA and CPAM Meeting Request' form. On the left is an 'APPLICATION BUILDER' sidebar with tabs for 'Contact Details', 'Meeting Request Details' (selected), 'Product Details', 'Upload Documents', and 'Review & Submit'. Below this is a 'Need Help?' section. The main area is titled 'Meeting Request Details' and contains 'Meeting Request Information' fields. These include a dropdown for 'Please select the Meeting type for your request' with 'Pre-ANDA Meeting Request' selected. Below this is a question: 'What is the Pre-Assignment ANDA Number for this meeting request?'. There are also fields for 'Application Type' (set to 'ANDA') and 'Application Number' (with a 'Select an option' dropdown). Below these is a section for 'ANDA Information'. A dropdown menu for 'What is the type for this Pre-ANDA Meeting Request?' is highlighted with a blue box and shows 'Pre-ANDA Product Development Meeting' selected. Below this are three other options: 'Pre-ANDA Product Development Meeting', 'ANDA Pre-Submission Meeting', and 'Pre-Submission PSG Teleconference'. To the right of these options is a text area for 'Attachments to demonstrate...'. At the bottom, there is a question: 'What is the type for this Pre-ANDA Meeting Request?'.

What's New? CDER NextGen Portal – Pre-Launch Activities Importation Requests (PLAIR)




Section 505(A) of the FD&C Act prohibits the introduction of any new drug into interstate commerce unless there is an approved application filed for that drug; however, Industry can submit a pre-launch activities importation request (PLAIR) in preparation for market launch within 60 days of the anticipated decision date for a pending initial original marketing application.

- Stakeholders be able to submit a PLAIRs in preparation for market launch within 60 days
- 2 way communication enabled for efficient collaboration (e.g. Information Request, Clarification, final response letter etc.)

FDA CDER NextGen Portal User Adoption

The CDER NextGen Portal Team continue to make enhancements to improve user's experience



In Summary :

1) What is CDER NextGen Portal?

- One stop shop for the purpose of non-eCTD Submission, Collaboration and Reporting.

2) What's New?

- CARES Volume Act
- Controlled Correspondences
- Pre-ANDA Meeting Request (CPAM)
- Pre-Launch Activities Importation Requests (PLAIR)

3) User Experience & Adoption

- Over 12k users & 100k plus submissions

How to Access NextGen Portal?

New Users

Sign up CDER NextGen Portal, navigate to <https://cdernextgenportal.fda.gov> and follow the signup instructions



Don't have an account? [Sign up](#)



Thank You

